A new U.S. Senate report, released by Sen. Bernie Sanders, found that drug companies involved in price deals with President Donald Trump have continued to raise prices on hundreds of meds.
Apr 20, 2026
0
5
A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II ...
Apr 20, 2026
0
5
A recent study published in Cell Reports Medicine has identified distinct microbial signatures within the oral cavity and gut that serve as robust biomarkers for the early detection of gastric cancer (GC).
Apr 20, 2026
0
3
Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 ...
Apr 20, 2026
0
2
An artificial intelligence (AI) model developed by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ability to accurately predict responses to immunotherapy for patients with metastatic non-small ...
Apr 20, 2026
0
4
A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC), according to a ...
Apr 20, 2026
0
3
A machine learning model analyzing CpG-based DNA methylation accurately predicted the origin of many different cancer types in patients with cancers of unknown primary (CUP), according to research presented at the American ...
Apr 20, 2026
0
3
The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D ...
Apr 20, 2026
0
5
Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy beyond the standard two years, according ...
Apr 20, 2026
0
4
Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according ...
Apr 20, 2026
0
5
